



***A SwedenBIO analysis of the clinical development
pipeline in the Swedish biotech industry
Feb, 2005***

Co-sponsor:




SwedenBIO
Wallingatan 24
S-111 24 Stockholm
Office +46 8 213601-02
www.swedenbio.com


A Survey of the Swedish Biotech pipeline

- A survey of the drug pipeline of Swedish biotech companies was conducted in January 2005. A similar study was done in 2004 with support from Vinnova
- The survey was conducted by SwedenBIO and co-financed partly by Invest in Sweden Agency (ISA)
- Results are impressive: 29 Swedish projects are in clinical trials and as many as 32 CD's are in late pre-clinical trials (6-12 months from CT)
- This is a significant increase from 2004 results
- SwedenBIO and ISA will use the results to promote Swedish biotech industry internationally and to generate business contacts
- Interested parties can contact SwedenBIO or ISA for more information. Details are available on www.swedenbio.com

The Swedish biotech pipeline has 29 projects in clinical trials




The dominating therapeutic categories are autoimmune disorders and HIV




Source: Interviews, SwedenBIO analysis Jan-05
 Note: Graph includes drugs from late pre-clinical phase to phase three

The majority of projects in development by Swedish biotech companies are small molecules




The majority of projects originate from internal research or in limited collaboration with academia




Source: Interviews, SwedenBIO Jan-05

The majority of the production for clinical trials has been established abroad



Most companies perform at least some clinical trials in Sweden



AstraZeneca has 54 projects in clinical trials which is about twice the total no. of clinical projects in Swedish biotech companies

